Hepatitis C News and Research

Latest Hepatitis C News and Research

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

Former President Clinton awards certification for new clean water system

The first chlorination system designed for cities in poor countries is now operating in Port-au-Prince, Haiti, announced Andrew Weiss at the Clinton Global Initiative (CGI) meeting in New York last week. "It's a great success," said Weiss.

5 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

New technique for blood diagnosis developed

If a person loses a large amount of blood the consequences can be critical. That's why adequate quantities of donated blood have to be kept available in hospitals and blood banks.

3 Oct 2009

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.

3 Oct 2009

New study underscores lack of appropriate government action to ensure safety of vaccines

A new study in the leading scientific journal NeuroToxicology lends further credence to parents and scientists concerned about an increasingly aggressive childhood vaccine schedule and toxic vaccine components.

2 Oct 2009

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has received a patent from China's State Intellectual Property Bureau for its Aoxing Ganbao product. The patent number is 551073.

2 Oct 2009

New improved marker-free technique provides faster blood analysis

The analysis takes just a few minutes and the doctor knows straight-away whether there are any pathogens in the blood. An improved marker-free technique provides the basis for faster analysis, whether in a hospital or for mobile blood donations.

1 Oct 2009

Danya International bags contract to operate NPIN for CDC

Danya International, Inc., a communications, research, and technology firm, has been awarded a contract to continue its performance in operating the National Prevention Information Network (NPIN) for the Centers for Disease Control and Prevention (CDC). NPIN provides the latest information, resources, and technology focused on preventing HIV/AIDS, viral hepatitis, STDs, and tuberculosis.

1 Oct 2009

Stanford Hospital invests $3 million in technology for safe patient handling

Swaddled in a cushy green hammock, the patient began her ascent off the bed. While one nurse regulated the speed of the lifting device, two of his colleagues guided the patient toward a bedside chair. Within seconds, she was securely lowered onto a cushion, and ready to begin rehabilitation exercises.

1 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

ABL partners with Evivar Medical to develop and commercialize clinical management tools

Advanced Biological Laboratories S.A (ABL) and Evivar Medical Pty Ltd (Evivar) today announced the completion of agreements to cross-licence their respective intellectual property portfolios, and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis B.

30 Sep 2009

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) to study two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury.

29 Sep 2009

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

29 Sep 2009

Biomagnetics Diagnostics to develop handheld testing platform for malaria and bovine TB

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million from investors and an anonymous philanthropic source. These funds will be used to further develop the company’s unique handheld testing platform targeting the areas of malaria and bovine tuberculosis testing.

29 Sep 2009

Hygafem's hand sanitizing program launched at Morehouse College

Hygafem, Inc., the Georgia-based premier provider of touch-free workplace wellness technologies and services, has successfully launched its hand sanitizing program at Morehouse College in Atlanta, GA. Hygafem’s touch-free hand sanitizing program decreases the risk of spreading disease, ensures safe and healthy facilities, and boosts satisfaction for students and employees at Morehouse College.

29 Sep 2009

Protection of front-line healthcare workers compromised

According to George Kappler, "If hospitals were subjected to the same protection standards as factories, many would have been shut down a long time ago." Those are tough words for healthcare workers to hear as they brace for an onslaught of H1N1 patients, but the CEO of Kappler, Inc., a 33-year veteran in the protective garment business, knows of what he speaks.

29 Sep 2009

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals Incorporated today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston.

25 Sep 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Preclinical study results of AVL-181 protease inhibitor presented

NanoViricides completes a number of financing activities

Former President Clinton awards certification for new clean water system

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New technique for blood diagnosis developed

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

New study underscores lack of appropriate government action to ensure safety of vaccines

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

New improved marker-free technique provides faster blood analysis

Danya International bags contract to operate NPIN for CDC

Stanford Hospital invests $3 million in technology for safe patient handling

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

ABL partners with Evivar Medical to develop and commercialize clinical management tools

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Biomagnetics Diagnostics to develop handheld testing platform for malaria and bovine TB

Hygafem's hand sanitizing program launched at Morehouse College

Protection of front-line healthcare workers compromised

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in